Morphine Dosing for Comfort Measures Only (CMO)
For opioid-naïve patients on CMO, start with morphine sulfate immediate-release 2.5-5 mg orally every 2-4 hours as needed, or 1-2 mg subcutaneously every 2-4 hours as needed if unable to swallow. 1
Initial Dosing Strategy
For Patients Able to Swallow (Opioid-Naïve)
- Start with morphine sulfate immediate-release 2.5-5 mg PO every 2-4 hours as needed 1
- Alternative: Morphine sulfate modified-release 5 mg twice daily, increased as necessary (maximum 30 mg daily) 1
- The lower end of this range (2.5 mg) is particularly appropriate for frail or elderly patients 1
For Patients Unable to Swallow (Opioid-Naïve)
- Morphine sulfate 1-2 mg subcutaneously every 2-4 hours as needed 1
- If needed frequently (more than twice daily), consider subcutaneous infusion via syringe driver starting with morphine sulfate 10 mg over 24 hours 1
- The oral to subcutaneous conversion ratio is approximately 1:2 to 1:3 2
For Patients Already on Regular Opioids
- Morphine sulfate immediate-release 5-10 mg PO every 2-4 hours as needed 1
- Or use one-twelfth of the 24-hour dose for pain, whichever is greater 1
Key Dosing Principles for CMO
The CMO context differs from standard cancer pain management in several critical ways:
- Intermittent dosing is often appropriate when breathlessness or discomfort is not continuous 1
- Rescue doses can be given as frequently as hourly if needed 1, 2
- Titrate upward based on symptom control, not predetermined schedules—review total daily morphine use and adjust the regular dose accordingly 2
Special Considerations
Renal Impairment
- If eGFR <30 mL/min, use equivalent doses of oxycodone instead of morphine to avoid accumulation of toxic metabolites 1
- Morphine-6-glucuronide accumulates in renal failure and can worsen adverse effects 3
Concomitant Medications
- Consider prophylactic antiemetic (such as haloperidol) 1
- Always prescribe a regular stimulant laxative (such as senna) 1, 2
- Constipation is the main continuing adverse effect and requires prophylaxis 2
Managing Breathlessness at End of Life
For moderate to severe breathlessness with distress in dying patients:
- Combine morphine with non-pharmacological strategies (positioning, pursed-lip breathing, fans, sitting upright) 1
- Add benzodiazepines if anxiety is present (lorazepam 0.5-1 mg PO q4h prn, maximum 4 mg/24h; reduce to 0.25-0.5 mg in elderly) 1
- Reduce excessive secretions with scopolamine, atropine, or glycopyrrolate 4
Common Pitfalls to Avoid
Do not use transdermal fentanyl patches in opioid-naïve CMO patients—the time to steady state is too long for symptom control in the dying process 1
Do not use modified-release formulations for initial titration—immediate-release formulations allow for rapid dose adjustments every 24 hours based on rescue dose requirements 2
Do not fear respiratory depression with appropriate dosing—when morphine is introduced gradually for symptom control, respiratory depression is rare 5, 6. Initial drowsiness typically resolves within a few days 2
Do not underdose due to unfounded addiction concerns—physical dependence and psychological addiction are rare in palliative care settings 6
Route Selection Algorithm
- Oral route is preferred when patient can swallow 2
- Subcutaneous route if unable to swallow or poor oral absorption 2
- Intravenous route only if patient already has IV access or has poor peripheral circulation 2
- Rectal route has 1:1 bioavailability with oral but is less commonly used 5
The subcutaneous route is simpler and less painful than intramuscular, which should be avoided 2
Dose Titration in Practice
Review the patient's total morphine consumption (regular plus rescue doses) every 24 hours and adjust the regular dose upward to account for rescue use 2. This individualized approach based on actual consumption is safer and more effective than predetermined dose escalation schedules 5.